Monoclonal antibodies in drug targeting

Journal of Clinical Pharmacy and Therapeutics

Volumn 22, Issue 1, 1997, Pages 7-19

  Panchagnula, R ^a   Dey, C S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIGOXIN ANTIBODY F(AB) FRAGMENT; DRUG ANTIBODY; IMMUNOTOXIN; MONOCLONAL ANTIBODY; VINCA ALKALOID;

ANTIBODY STRUCTURE; CANCER CHEMOTHERAPY; DIGITALIS INTOXICATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; REVIEW;

EID: 0030839728     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1997.96475964.x     Document Type: Review

References (142)

1. Friend DR, Pangburn S. (1987) Site specific drug delivery. Medical Research Reviews, 7, 53-106.
2. Hinman LM, Yarranton G. (1993) New approaches to non-immunogenic antibody cancer therapies. Annual Reports in Medicinal Chemistry, 28, 237-246.
3. Pimm MV. (1988) Drug-monoclonal antibody conjugates for cancer therapy: Potentials and limitations. CRC Critical Reviews in Therapeutic Drug Carrier Systems, 5, 189-227.
4. Baldwin RW. (1983) Monoclonal antibodies for drug targeting in cancer therapy. Pharmacy International, 4, 137-141.
5. Derbyshire EJ, Wawrzynczak EJ. (1992) An anti-mucin immunotoxin BrE-3-Ricin A chain is potently and selectively toxic to human small-cell lung cancer. International Journal of Cancer, 52, 624-630.
6. Dillman RO, Johnson DE, Shawler DL. (1988) Comparisons of drugs and immunoconjugates. Antibody Immunoconjugates and Radiopharmaceuticals, 1, 65-77.
7. Engert A, Barrowa F, Jung N, et al. (1990) Evaluation of Ricin A chain containing immunotoxins directed against the CD30 antigens as potential reagents for the treatment of Hodgkin's disease. Cancer Research, 50, 84-88.
8. Engert A, Martin G, Pfreundschuh M, et al. (1990) Antitumor effects of Ricin A chain immunotoxins prepared from intact antibodies and Fab fragments in solid human Hodgkin's disease tumors in mice. Cancer Research, 50, 2929-2935.
9. Vitetta ES, Fulton RJ, May RD, Till M, Uhr JN. (1987) Redesigning nature in poison to create anti-tumor reagents. Science, 238, 1098-1104.
10. Vitetta ES, Thorpe PE, Uhr JN. (1993) Immunotoxin: magic bullets or misguided missiles. Trends in Pharmacological Sciences, 14, 148-154.
11. Wawrzynczak EJ. (1991) Systemic immunotoxin therapy of cancer: advances and prospects. British Journal of Cancer, 64, 624-630.
12. Pietersz GA, Smith MJ, Kanells J, Cunningham Z, Sacks NPM, McKenzie IFC. (1988) Preclinical and clinical studies with a variety of immunoconjugates. Antibody Immunoconjugates and Radiopharmaceuticals, 1, 79-103.
13. Spitler L, delRio M, Khentigan A, et al. (1987) Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody Ricin A chain. Cancer Research, 47, 1717-1723.
14. McGargkey C. (1974) Feasibility of tumor immunotherapy using radioiodinated antibodies to tumor-specific cell membrane antigens with emphasis on leukemias and early metastases. Oncology, 29, 302-307.
15. Ballau B, Levine G, Hakala TR, Solter E. (1979) Tumor location detected with radioactively labeled monoclonal antibody and external scintigraphy. Science, 206, 844-846.
16. Order SL, Sleeper AM, Stillwagon GB, Klien JL, Leicher PK. (1990) Radiolabeled antibodies and potential cancer therapy. Cancer Research, 50 (Suppl.), 1011-1013.
17. Goldenberg DM, Larsom SM, Reisfeld RA, Schlom J. (1995) Targeting cancer with radiolabeled antibodies. Immunology Today, 16, 261-264.
18. Thomas H. (1992) New horizons in cancer therapy. Drugs of Today, 28, 311-331.
19. Brodsky FM. (1988) Monoclonal antibodies as magic bullets. Pharmaceutical Research, 5, 1-9.
20. Ganong WF. (1985) Review of Medical Physiology. pp. 426-427. Lange Medical Publications, Los Altos, CA.
21. Coding JW. (1983) Monoclonal Antibodies: Principles and Practice. pp. 7-10. Academic Press, New York.
22. Catty D. (1986) Antibodies Volume 1. A Practical Approach. pp. 6-17. IRL Press, Washington DC.
23. Harlow E, Lane D. (1988) Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, New York.
24. Kohler G, Milstein C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495-497.
25. Milstein C. (1980) Monoclonal antibodies. Scientific America, 243, 66-74.
26. Roitt IM. (1987) Essential Immunology. Blackwell Scientific Publications, Oxford.
27. Zola H. (1987) Monoclonal Antibodies: A Manual of Techniques. pp. 1-11. CRC Press Inc., Baco Raton, FL.
28. Herlyn M, Stepleweski Z, Herlyn D, Koprowski G. (1979) Colorectal carcinoma-specific antigen detection by means of monoclonal antibodies. Proceedings of the National Academy of Sciences of the USA, 76, 1438-1442.
29. Hockey MS, Stokes HJ, Thomson H, et al. (1984) Carcinoembryonic antigen (CEA) expression and heterogenicity in primary and autologous metastatic gastric tumors demonstrated by monoclonal antibodies. British Journal of Cancer, 49, 192-233.
30. Kennett RH, Gilbert F. (1979) Hybrid myelomas producing antibodies against a human neuroblastoma antigen present on fetal brain. Science, 203, 1120-1122.
31. Koprowaski G, Stepleweski Z, Herlyn D, Herlyn M. (1978) Study of antibodies against human melanoma produced by somatic cell hybrids. Proceedings of the National Academy of Sciences of the USA, 75, 3405-3409.
32. Rowland GF. (1983) The use of antibodies and polymer conjugates in drug targeting and synergy. In: Targeted Drugs. ed Goldberg E, pp. 57-72, John Wiley, New York.
33. Upeslacis J, Hinman L. (1988) Chemical modification of antibodies for cancer chemotherapy. Annual Reports in Medicinal Chemistry, 23, 151-160.
34. Mathe G, Loc TB, Bernard H. (1958) Effet sur la leucemic L1201 de la souris d'une combinaison par diszotation d'A-methopterine et de gamma-globulines de hamsters porteur de cette leucemie par hereogreffe. Comptes Rendues, 246, 1626-1628.
35. O'Neill GJ. (1979) The use of antibodies as drug carriers. In: Drug Carriers in Biology and Medicine. ed Gregoriadis G, pp. 23-41, Academic Press, London.
36. Hurwitz E, Levy R, Maron R, Wilchek M, Arnon R, Sela M. (1975) The covalent bonding of daunomycin and adriamycin to antibodies with retention of both drug and antibody activities. Cancer Research, 35, 1175-1181.
37. Ghose T, Norwell S, Guclu A, Cameron D, Bodurtha A, Macdonalds AS. (1972) Immunotherapy of cancer with chlorambucil carrying antibody. British Medical Journal, 3, 495-499.
38. Gallego J, Price MR, Baldwin RW. (1984) Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumor activity. International Journal of Cancer, 33, 737-744.
39. Yang HM, Reisfeld RA. (1988) Doxorubicin conjugated with monoclonal antibody directed to human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proceedings of the National Academy of Sciences of the USA, 85, 1189-1193.
40. Rowland GF. (1983) Use of antibodies target drugs to tumor cells. Clinics in Allergy and Immunology, 3, 235-257.
41. Arnon R, Hurwitz E. (1985) Monoclonal antibodies as carriers for immuno-targeting of drugs. In: Monoclonal Antibodies for Cancer Detection and Therapy. eds Baldwin RW, Bayer VS, pp. 367-383, Academic Press, London.
42. Worren W. (1992) Coupling of monoclonal antibodies. In: Monoclonal Antibodies. eds Peters JH, Baumgarten H, pp. 285-291, Springer-Verlag, Berlin.
43. Schlom J, Weeks MO. (1984) Potential clinical utility of monoclonal antibodies in the management of human carcinomas. In: Important Advances in Oncology. eds DeVita V, Halman S, Rosenberg S, pp. 170-192, J.B. Lippincot, Philadelphia.
44. Schlom J. (1988) Monoclonal antibodies in cancer therapy: the present and future. Biapharmacy, 9 (Sept.), 44-48; see also Pharmaceutical Technology, 88 (Sept.), 56-60.
45. Schlom J. (1988) Monoclonal antibodies in cancer therapy: the present and future. Biapharmacy, 9 (Sept.), 44-48; see also Pharmaceutical Technology, 88 (Sept.), 56-60.
46. Ghose T, Blair AH. (1978) Antibody-linked cytotoxic agents in the treatment of cancer. Journal of the National Cancer Institute, 61, 657-676.
47. Ghose T, Blair AH, Kulkarni P, Vaughan K, Norvell S, Beltitsky P. (1982) Targeting of radionucleotides and drugs for the diagnosis and treatment of cancer. In: NATO Advanced Study Institute Series A. Plenum Press, New York. Life Sciences, 47, 55-82.
48. Ghose T, Blair AH, Kulkarni P. (1983) Preparation of antibody-linked cytotoxic agents. Methods in Enzymology, 93, 280-283.
49. Ghose T, Blair AH, Uadia P, et al. (1985) Antibodies as carriers of cancer chemotherapeutic agents. Annals of New York Academy of Sciences, 446, 213-227.
50. 2 fragments and the effect of conjugate on tumor growth in vivo. Cancer Immunology Immunotherapy, 19, 211-216.
51. Embelton MJ. (1986) Targeting of anti-cancer therapeutic agents by monoclonal antibodies. Biochemical Society Transactions, 14, 393-396.
52. Endo N, Taketda Y, Kishida K, et al. (1987) Target selective cytotoxicity of methotrexate conjugates with monoclonal anti-MM46 antibody. Cancer Immunology Immunotherapy, 25, 1-6.
53. Garnett MC, Embelton MJ, Jacobs E, Baldwin RW. (1983) Preparation and properties of a drug-carrier - antibody conjugate showing selective antibody-directed cytotoxicity in vitro. International Journal of Cancer, 31, 661-670.
54. Smyth MJ, Pietersz GA, Classon BJ, McKenzie IFC. (1986) Specific targeting of chlorambucil to tumor with the use of monoclonal antibodies. Journal of the National Cancer Institute, 76, 503-540.
55. Smyth MJ, Pietersz GA, McKenzie IFC. (1987) Specific targeting of chlorambucil to tumor with the use of monoclonal antibodies. Cancer Research, 47, 62-67.
56. Hurwitz E, Schechter B, Arnon R, Sela M. (1979) Binding of anti-tumor immunoglobulins and their daunomycin conjugates to the tumor metastases, in vitro and in vivo studies with Lewis lung carcinoma. International Journal of Cancer, 24, 461-464.
57. Shih LB, Sharkey RM, Primus FJ, Goldberg DM. (1988) Site-specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier. International Journal of Cancer, 41, 832-839.
58. Tsukada Y, Ohkawa K, Hibi N. (1987) Therapeutic effect of treatment with polyclonal or monoclonal antibodies to α-fetoprotein that have been conjugated to daunomycin via dextran bridge: studies with an α-fetoprotein-producing rat hepatoma tumor model. Cancer Research, 47, 4293-4295.
59. Arnon R. (1982) Targeting of Drugs. eds Gregoriadis G, Senior J, Trouet A, p. 31, Plenum Press, New York.
60. Tai J, Blair AH, Chose T. (1979) Tumor inhibition by chlorambucil covalently linked antitumor globulin. European Journal of Cancer, 15, 1357-1361.
61. 2 conjugates. British Journal of Cancer, 55, 7-11.
62. Chose T, Guclu A, Raman RR, Blair AH. (1982) Inhibition of mouse hepatoma by alkylating agent trenimon linked to immunoglobulins. Cancer Immunology Immunotherapy, 13, 185-109.
63. Rowland AJ, McKenzie IF, Pietersz GA. (1993) Enhanced antitumor effects using a combination of two antibodies conjugated to two different drugs. Journal of Drug Targeting, 2, 113-121.
64. Schechter B, Pauzner R, Arnon R, Haimovich J, Wilcheck M. (1987) Selective cytotoxicity against tumor cells by cisplatin complexed to antitumor antibodies via carboxymetheyl dextran. Cancer Immunology Immunotherapy, 25, 225-230.
65. Isreal M, Modest EJ, Frei E. (1975) N-Trifluoroacetyl adriamycin 14-veleraten an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Research, 35, 1365-1368.
66. Pietersz GA, Smyth MJ, MaKenzie TFC. (1988) The use of anthracycline-antibody complexes for specific antitumor activity. In: Antibody-Mediated Delivery Systems. ed Rodwell JD, pp. 25-53, Marcel Dekker, Basel.
67. Pimm MV, Jones JA, Price MR, Middle JG, Embleton MJ, Baldwin RW. (1982) Tumor localization of monoclonal antibody against a rat mammary carcinoma and suppression of tumor growth with adriamycin-antibody conjugates. Cancer Immunology Immunotherapy, 12, 125-129.
68. Tsukada Y, Kato Y, Takeda Y, Hara T, Hirai H. (1984) An anti α-fetoprotein antibody-daunorubicin conjugate with a novel poly-L-glutamic acid derivative as an intermediate drug carrier. Journal of the National Cancer Institute, 73, 721-728.
69. Trail PA, Willner D, Lasch SJ, et al. (1993) Cure of xenografted carcinomas by BR-96-doxorubicin immunoconjugates. Science, 261, 212-215.
70. Young RC, Ozols RF, Myers CE. (1981) The anthracycline antineoplastic drugs. New England Journal of Medicine, 305, 139-153.
71. Hurwitz E, Kashi R, Arnon R, Wilcheck M, Sela M. (1985) The covalent linking of two nucleotide analogues to antibodies. Journal Medicinal Chemistry, 28, 137-140.
72. Chari RV, Martell BA, Gross JL, et al. (1992) Immunoconjugates containing novel maylansinoids: Promising anticancer drugs. Cancer Research, 52, 127-131.
73. 4-blocked ricin immunotoxin shows therapeutic efficacy in four SCID mouse tumor model. Cancer Research, 56, 1360-1367.
74. 1 and calicheamicin T. Proceedings of the National Academy of Sciences of the USA, 89, 4608-4612.
75. 11: an antitumor antibiotic that cleaves double strand DNA site specific. Science, 240, 1198-1201.
76. 11 and DNA: molecular recognition process responsible for site-specificity. Science, 244, 697-699.
77. Pimm MV, Clegg JA, Garnett MC, Baldwin RW. (1988) Biodistribution and tumor localization of methotrexate-monoclonal antibody 791T/36 conjugate in nude mice with human tumor xenografts. International Journal of Cancer, 41, 886-891.
78. Ballantyne KC, Perkins AC, Pimm MV, et al. (1988) Biodistribution of monoclonal antibody-methotrexate conjugate (791T/36-MTX) in patients with colorectal cancer. International Journal of Cancer, (Suppl. 2), 103-108.
79. Affleck K, Embleton MJ. (1992) Monoclonal antibody targeting of methotrexate (MTX) against MTX-resistant tumor cell lines. British Journal of Cancer, 65, 834-844.
80. Philpott GW, Gass EH, Panker CW. (1979) Affinity cytotoxicity with an alcohol dehydrogenase-antibody conjugate and allyl alcohol. Cancer Research, 39, 2084-2087.
81. Rowland GF, Corvalan JRF, Axton CA, et al. (1984) Suppression of growth of human colorectal tumor in nude mice by vindesine-monoclonal antiCEA conjugates. Protides of Biological Fluids, 31, 783-786.
82. Rowland GF, Axton CA, Baldwin RW, et al. (1985) Antitumor properties of vindesine-monoclonal antibody conjugates. Cancer Immunology Immunotherapy, 19, 1-7.
83. Rowland GF, Simmonds RG, Grove VA, Mardsen CH, Smith W. (1986) Drug localization and growth inhibition studies of vindesine-monoclonal anti-CEA conjugates in human xenograft. Cancer Immunology Immunotherapy, 21, 183-187.
84. Casson AG, Ford CHJ, Mardsen CH, Gallant ME, Barrlett SE. (1987) Efficacy and selectivity of vindesine monoclonal anti-carcinoembryonic antigen antibody conjugates on human tumor cell lines grow as xenograft in nude mice. National Cancer Institute Monographs, 3, 117-124.
85. Smith TW. (1985) Antitumor properties of vindesine-monoclonal antibody conjugates. Cancer Immunology Immunotherapy, 19, 1-7.
86. Ghetice V, Vitetta E. (1994) Immunotoxins in therapy of cancer: From bench to clinic. Pharmacology and Therapeutics, 63, 209-234.
87. Ribi HO, Ludwig DS, Mercer KL, Schoolnik GK, Kornberg RD. (1988) Three-dimensional structural of cholera toxin penetrating a lipid membrane. Science, 239, 1272-1276.
88. Pastan I, Willingham MC, Fitzgerald DJP. (1986) Immunotoxins. Cell, 48, 641-648.
89. Olsnes S, Moskang JO, Stenmerk H, Sandvig K. (1988) Diphtheria toxin entry: protein translocation in the reverse direction. Trends in Biological Sciences, 13, 348-351.
90. Clemens M. (1984) Enzymes and toxins that regulate protein synthesis. Nature, 310, 727-729.
91. Byers VS, Rodvin R, Grant H. (1969) Phase I study of monoclonal antibody Ricin A chain immunotoxin xomazyme in 791 patients with metastatic colon cancer. Cancer Research, 49, 6153-6158.
92. Hertler AA, Frankel AE. (1989) Immunotoxins, a clinical review of their use in the treatment of malignancies. Journal of Clinical Oncology, 7, 1932-1939.
93. Von Wussow P, Spitker L, Blach B, Deicher H. (1988) Immunotherapy in patients with advanced malignant melanoma using a monoclonal antimelanoma antibody Ricin A chain immunotoxin. European Journal of Cancer and Clinical Oncology, 24 (Suppl. 2), 69-74.
94. Weiner LM, O'Dwyer J, Kitson J. (1989) Phase I re-evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant Ricin A chain immuno-conjugate. Cancer Research, 49, 4062-4066.
95. Vitetta ES, Yen N. (1990) Expression of functional properties of genetically engineering Ricin B chain lacking galactose binding ability. Biochemica et Biophysica Acta, 1049, 151-155.
96. Chaudhary VK, Galeo MG, Fitzgerald DJ, Pastan I. (1990) A recombinant single chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin. Proceedings of the National Academy of Sciences of the USA, 87, 9491-9494.
97. Stanislawski M, Rousseau V, Goavee M, Ito H. (1989) Immunotoxins containing glucose oxidase and lactoperoxidase with tumoricidal properties: In vitro killing effectiveness in a mouse plasmacytoma model. Cancer Research, 49, 5497-5504.
98. Senter PD, Saulnier MG, Schreiber GJ, et al. (1988) Antitumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proceedings of the National Academy of Sciences of the USA, 85, 4842-4846.
99. Colburn WA. (1980) Specific antibodies and Fab fragments to alter pharmacokinetics and reverse the pharmacologic/toxicologic effects of drugs. Drug Metabolism Reviews, 11, 223-262.
100. Smith TW, Haber E, Yeatman L, Butler JR V. (1976) Reversal of advanced digoxin intoxication with Fab fragments of digoxin specific antibodies. New England Journal of Medicine, 294, 797-800.
101. Smith TW, Butler JR V, Haber F, Fozzard H, Marcus FI. (1982) Treatment of life threatening digitalis intoxication with digoxin-specific Fab antibody fragments. New England Journal of Medicine, 307, 1357-1362.
102. Wenger TL, Butler VP, Haber E, Smith TW. (1985) Treatment of 63 severely digitalis-toxic patients with digoxin-specific antibody fragments. Journal of American Colleges of Cardiology, 5 (Abstract), 118-123.
103. Schwartz A, Lindenmayer GE, Allen JC. (1975) The sodium-potassium adenosine triphosphate: pharmacological, physiological and biochemical aspects. Pharmacological Reviews, 27, 3-134.
104. Ochs HR, Smith TW. (1977) Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. Journal of Clinical Investigation, 60, 1303-1313.
105. Antman EM, Wenger TL, Butler JR VP, Haber E, Smith TW. (1990) Treatment of 150 cases of life-threatening digitalis intoxication with digoxin specific Fab antibody fragments: Final report of a multi center report. Circulation, 81, 1744-1752.
106. Sabouraud A, Scherrmann JM. (1993) Immunotherapy of drug intoxications. Therapie, 49, 41-48.
107. Urtizberea M, Sabouraud A, Grandgeorge M, Rouzious JM, Scherrmann JM. (1991) Colchicine toxicity by colchicine specific Fab fragments. Toxicology Letters, 58, 193-198.
108. Chen N, Bowles MR, Pond SM. (1994) Prevention of paraquat in suspension of alveolar type II cell by paraquat-specific antibodies. Human Experimental Toxicology, 3, 551-557.
109. Owens SM, Mayersohn M. (1986) Phencyclidine-specific Fab fragments alter pheneyclidine disposition in dogs. Drug Metabolism and Disposition, 14, 52-58.
110. 2 fragment reduces imipramine cardiotoxicity in rats. International Journal of Immunopharmacology, 13, 841-851.
111. Brunn GJ, Keyler DE, Pond SM, Pentel PR. (1992) Reversal desimipramine toxicity in rats using drug-specific antibody Fab' fragments. Effects of hypotension and interaction with sodium bicarbonate. Journal of Pharmacology and Experimental Therapeutics, 260, 1392-1399.
112. Pentel PR, Ross CA, Landon J, Sidki A, Shelver WL, Keyler DE. (1994) Reversal of desimipramine in rats using polyclonal-drug specific antibody fragments. Journal of Laboratory and Clinical Medicine, 123, 387-393.
113. Keyler DE, Le Couleur DG, Pond SM, Peter ST, Pentel PR. (1995) Effects of specific antibody Fab fragments on desimipramine pharmacokinetics in rat in vivo and in isolated, perfused liver. Journal of Pharmacology and Experimental Therapeutics, 272, 1117-1123.
114. Hajela K, Galzie Z. (1991) Designer antibodies. Biotechnological Education, 2, 154-161.
115. Winter G, Harris WJ. (1993) Humanized antibodies. Trends in Pharmacological Sciences, 14, 139-143.
116. Nishoka Y, Sone S, Heike Y, et al. (1992) Effector cell analysis of human multidrug resistant cell killing by mouse-human chimeric antibody against P-glycoprotein. Japanese Journal of Cancer Research, 83, 644-649.
117. Ariyoshi K, Hamada H, Naito M, et al. (1992) Mouse-human chimeric antibody MH171 against the multidrug transporter P-glycoprotein. Japanese Journal of Cancer Research, 83, 515-521.
118. Olsson L, Kaplan H. (1981) Human-human hybridoma secretory monoclonal antibody on predefined antigen specificity. Proceedings of the National Academy of Sciences of the USA, 78, 3199-3202.
119. Isaccs JD, Watts RA, Hazleman BL, et al. (1992) Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet, 340, 748-752.
120. Adair JR. (1992) Engineering antibodies for therapy. Immunological Reviews, 130, 5-40.
121. Co MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C. (1992) Chimeric and humanized antibodies with specificity for CD33 antigen. Journal of Immunology, 148, 1149-1154.
122. HER2 antibody for human cancer therapy. Proceedings of the National Academy of Sciences of the USA, 89, 4285-4289.
123. Riechman L, Clark M, Waldmen H, Winter G. (1988) Reshaping human antibodies for therapy. Nature, 332, 323-327.
124. Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Reichmann L, Winter G, Waldmann N. (1988) Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet, ii, 1394-1399.
125. Mathieson PW, Cabbold SP, Hale G, et al. (1990) Monoclonal antibody therapy in systemic vasculitis. New England Journal of Medicine, 332, 250-254.
126. Tempest PR, Bnenner P, Lambert M, Taylor G, Furze JM, Carr FJ, Harris WJ. (1991) Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biological Technology, 9, 266-271.
127. Borrebaeck AK, Danielsson L, Moller SA. (1988) Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes. Proceedings of the National Academy of Sciences of the USA, 85, 3995-3999.
128. Neuberger MS, Williams GT, Fox RO. (1984) Recombinant antibodies possessing novel effector functions. Nature, 312, 604-608.
129. Bode C, Matsueda G, Hui K, Haber E. (1985) Targeted thrombolysis with a fibrin specific antibody-urokinase conjugate. Science, 229, 765-767.
130. Schnee JM, Runge MS, Matsueda G, et al. (1987) Construction and expression of a recombinant antibody targeted plasminogen activator. Proceedings of the National Academy of Sciences of the USA, 84, 6904-6908.
131. Byrn RA, Mordentii J, Lucas C, et al. (1990) Biological properties of CD4 immunoadhesin. Nature, 344, 667-670.
132. Capon DJ, Channow SM, Mordentii J, et al. (1989) Designing CD4 immunoadhesin for AIDS therapy. Nature, 337, 525-531.
133. 2 reactive with P-glycoprotein and CD3 of cytotoxicity of human effector cells in P-glycoprotein positive human renal cancer cells. Japanese Journal of Cancer Research, 83, 366-372.
134. Pearson CK, Cunningham C. (1993) Multidrug resistance during cancer chemotherapy: biotechnological solutions to a clinical problem. Trends in Biotechnology, 11, 511-516.
135. Jung G, Ledbetter JA, Muller-Eberhard HJ. (1987) Induction of cytotoxicity in resting human T-lymphocytes bound to tumor cells by antibody heteroconjugates. Proceedings of the National Academic of Sciences of the USA, 84, 4611-4615.
136. Drakemen DL, Fanger MW. (1995) Bispecific antibodies and targeted cellular toxicity. Drug News and Perspectives, 8, 189-192.
137. Fanger MW, Drakeman DL. (1995) Bispecific antibodies. Drug News and Perspectives, 8, 133-137.
138. Ward ES, Gusson D, Griffith AD, Jones PT, Winter G. (1989) Binding activities of a reportoire of single immunoglobulin variable domain secreted from Escherichia coli. Nature, 341, 544-546.
139. Brunt JV. (1990) Amplifying genes: PCR and its alternatives. Biotechnology, 8, 291-294.
140. Griffiths AD, Malmqvist M, Marks JD, et al. (1993) Human antidelf antibodies with high specificity from phage display library. EMBO Journal, 12, 725-735.
141. Huse WD, Sastry L, Iverson SA, et al. (1989) Generation of a large combinatorial library of the immunoglobulins reportoire in phage lambda. Science, 246, 1275-1281.
142. Heaver GA. (1992) Monoclonal antibodies in therapy. Annual Reports in Medicinal Chemistry, 27, 179-188.